|
Q3 FY2026
As of Jun 30, 2026
|
Q2 FY2026
As of Mar 31, 2026
|
Q1 FY2026
As of Dec 31, 2025
|
Q4 FY2025
As of Sep 30, 2025
|
Q3 FY2025
As of Jun 30, 2025
|
Q2 FY2025
As of Mar 31, 2025
|
Q1 FY2025
As of Dec 31, 2024
|
Q4 FY2024
As of Sep 30, 2024
|
Q3 FY2024
As of Jun 30, 2024
|
Q2 FY2024
As of Mar 31, 2024
|
Q1 FY2024
As of Dec 31, 2023
|
Q4 FY2023
As of Sep 30, 2023
|
Q3 FY2023
As of Jun 30, 2023
|
Q2 FY2023
As of Mar 31, 2023
|
Q1 FY2023
As of Dec 31, 2022
|
Q4 FY2022
As of Sep 30, 2022
|
Q3 FY2022
As of Jun 30, 2022
|
Q2 FY2022
As of Mar 31, 2022
|
Q1 FY2022
As of Dec 31, 2021
|
Q4 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Short-term marketable securities | ||||||||||||||||||||
| Accounts receivable, net of allowance for expected credit losses ($3,842 and $4,649, respectively) | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Derivative asset | ||||||||||||||||||||
| Short-term restricted cash | ||||||||||||||||||||
| Refundable income taxes | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Current assets held for sale | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||||
| Long-term marketable securities | ||||||||||||||||||||
| Long-term deferred tax assets | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Long-term income taxes receivable | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Noncurrent assets held for sale | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and stockholders' equity | ||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Derivative liability | ||||||||||||||||||||
| Accrued warranty and retrofit costs | ||||||||||||||||||||
| Accrued compensation and benefits | ||||||||||||||||||||
| Customer deposits | ||||||||||||||||||||
| Accrued VAT payable | ||||||||||||||||||||
| Accrued income taxes payable | ||||||||||||||||||||
| Short-term operating lease liability | ||||||||||||||||||||
| Deposit received for the sale of B Medical Systems business | ||||||||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||||||||
| Current liabilities held for sale | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term tax reserves | ||||||||||||||||||||
| Long-term deferred tax liabilities | ||||||||||||||||||||
| Long-term operating lease liabilities | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| Noncurrent liabilities held for sale | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders' equity | ||||||||||||||||||||
| Preferred stock, $0.01 par value - 1,000,000 shares authorized, no shares issued or outstanding | ||||||||||||||||||||
| Common stock, $0.01 par value - 125,000,000 shares authorized, 57,226,616 shares issued and 43,764,747 shares outstanding at June 30, 2026; 59,320,848 shares issued and 45,858,979 shares outstanding at September 30, 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Treasury stock, at cost - 13,461,869 shares at June 30, 2026 and September 30, 2025 | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total liabilities and stockholders' equity | ||||||||||||||||||||
Loading...
